McMaster Faculty of Health Sciences

LIB Therapeutics Announces Positive Results from the Phase 3 Long-term Efficacy and Safety of Lerodalcibep in Heterozygous Familial Hypercholesterolemia (LIBerate-HeFH) Trial

Retrieved on: 
Monday, August 28, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Managed Care, Health, Clinical Trials, Faculty, Liberation, University, Cardiovascular disease, European Society of Cardiology, CVD, McMaster Faculty of Health Sciences, Patient, Guideline, European Heart Journal, Carbohydrate, Outline of health sciences, Disease, PCSK9, Mortality, LIB, Therapy, Pharmaceutical industry

The results from the large global Phase 3 randomized, placebo-controlled trial, of lerodalcibep, the company’s monthly small binding protein PCSK9 inhibitor, in patients with heterozygous familial hypercholesterolemia (HeFH) were presented today at the European Society of Cardiology and simultaneously published in the European Heart Journal.

Key Points: 
  • The results from the large global Phase 3 randomized, placebo-controlled trial, of lerodalcibep, the company’s monthly small binding protein PCSK9 inhibitor, in patients with heterozygous familial hypercholesterolemia (HeFH) were presented today at the European Society of Cardiology and simultaneously published in the European Heart Journal.
  • The trial enrolled 478 adult participants, who were randomized 2:1 to receive lerodalcibep or placebo for a 24-week treatment period.
  • The mean reduction in Apolipoprotein B of 45.6% and median reduction in Lp(a) of 24% compared to patients treated with placebo were statistically significant (p
  • Lerodalcibep was well-tolerated, with a safety profile generally comparable to placebo with only mild injection site adverse events being observed more frequently than placebo.

International Photodynamic Association Announces 2023 Award Recipients in Tampere, Finland

Retrieved on: 
Monday, July 17, 2023
Science, Biotechnology, Research, Oncology, Health, Medical Devices, Infectious Diseases, Clinical Trials, Radium, Faculty, Infection, UCL, PIT, University, PD, PDT, PDD, Government, MICHAEL, McMaster Faculty of Health Sciences, IPA, Congress, Student, Outline of health sciences, University of Johannesburg, Diagnosis, Hospital, Photodynamic therapy, Institute for Cancer Research, Pharmaceutical industry, Forestry

The IPA World Congress featured research on a number of areas that use light-activated photosensitizers, including photodynamic therapy (PDT), antimicrobial photodisinfection, photoimmunotherapy (PIT), photodiagnosis (PD), etc.

Key Points: 
  • The IPA World Congress featured research on a number of areas that use light-activated photosensitizers, including photodynamic therapy (PDT), antimicrobial photodisinfection, photoimmunotherapy (PIT), photodiagnosis (PD), etc.
  • The International Photodynamic Association (IPA) was founded in 1986 to support and endorse the scientific advancement and clinical development of photomedicine, in particular in the areas of photodynamic disinfection, photodynamic therapy (PDT), photoimmunotherapy (PIT), and photodiagnosis (PD).
  • For more information, please go to the site: International Photodynamic Association (IPA)
    The Biennial International Photodynamic Association World Congress aims to bring together researchers and clinicians in all fields of Photodynamic Therapy (PDT) and Photodiagnosis (PDD) since 1986.
  • The 18th IPA World Congress will be held in Tampere, Finland , July 10-15, 2023.

Gritstone to Host Data Update on CORAL and Discuss the Application of Self-amplifying mRNA (samRNA) in Infectious Diseases

Retrieved on: 
Wednesday, October 19, 2022
Fred Hutchinson Cancer Research Center, National Institute, U.S. Securities and Exchange Commission, RNA transfection, CEPI, Severe acute respiratory syndrome coronavirus 2, Annual report, Volunteering, CORAL, Infection, NIAID, Security (finance), Program, University of the Witwatersrand, University, Faculty, Immune system, UK, Epidemic, McMaster Faculty of Health Sciences, Degenerative disease, Virology, Q&A, Outline of health sciences, Bill & Melinda Gates Foundation, GLOBE, National Institute of Allergy and Infectious Diseases, COVID-19, COVID-19 vaccine, Pharmaceutical industry, Vaccine, Online shopping, Vaccine, Gritstone

EMERYVILLE, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that it will host a webinar on October 25, 2022 to present data from its CORAL program and discuss the application of its self-amplifying mRNA (samRNA) vaccine platform for infectious diseases. During the webinar, lead investigators will present data from the ongoing Phase 1 CORAL-BOOST and CORAL-CEPI trials which are evaluating the company’s samRNA vaccine candidates against SARS-CoV-2. Following the data presentations, Lawrence “Larry” Corey, M.D., an internationally renowned expert in virology, immunology and vaccine development, will speak to the potential application of samRNA vaccines against infectious diseases.

Key Points: 
  • Following the data presentations, Lawrence Larry Corey, M.D., an internationally renowned expert in virology, immunology and vaccine development, will speak to the potential application of samRNA vaccines against infectious diseases.
  • Professor Andrew Ustianowski, National Clinical Lead for the UK NIHR COVID Vaccine Research Programme, will present data from CORAL-BOOST.
  • Company management will also provide an overview of self-amplifying mRNA (samRNA) as a novel vaccine platform for the prevention and treatment of infectious diseases.
  • The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof.

Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022

Retrieved on: 
Monday, April 25, 2022
EMA, Nitric oxide, NTM, Respiratory syncytial virus, Marketing, Pulmonology, Artery, Population, COVID-19, Adult, RSV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ben-Gurion University of the Negev, Annual report, Urinary tract infection, Nontuberculous mycobacteria, Bacteria, Mycobacterium, Food, Outline of health sciences, Patient, Fungus, CAVP, Parasitism, Atmosphere of Earth, Technology, Company, SEC, Forward-looking statement, Faculty, McMaster Faculty of Health Sciences, Bronchiolitis, Mark (given name), Pulmonary hypertension, Safety, Hypoxemia, Beersheba, Policy, Respiratory distress syndrome, FDA, PAS, Virus, NO, Time, NO2, Pharmaceutical industry, Vaccine

The Beyond Air team continues to execute in this challenging pandemic environment and move the Beyond Air pipeline forward.

Key Points: 
  • The Beyond Air team continues to execute in this challenging pandemic environment and move the Beyond Air pipeline forward.
  • Professor, Head of Department Pediatrics, Soroka University Medical Center; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Dr. Goldbart presented the results of the long-term study at the PAS 2022 Meeting in an oral presentation titled, 1179165 Long-term effects of inhaled nitric oxide in infants with bronchiolitis a multi center study.
  • The presentation is available on the Events page of the Beyond Air website ( click here ).

Atos and Huma support Symbiosis Hospital in Pune to expand care capacity by up to 60% with new remote patient app

Retrieved on: 
Wednesday, December 1, 2021
Patient, Euronext Paris, National Digital Preservation Program, SIU, CEO, Heart rate, Technology, Biomarker, Outline of health sciences, Health care, Hospital, Population, Awareness, Partnership, Societas Europaea, ESG, Group, Heart of England NHS Foundation Trust, Education, Faculty, Solution, SE, Founder, COVID-19, Society, CAC, Research, National Digital Health Mission, CAC Next 20, Telehealth, Digital technology, Symbiosis International University, Smartphone, Digital, Knowledge, RADIUS, Disease, McMaster Faculty of Health Sciences, National, Pharmaceutical industry

This 'hospital at home' will allow the SUHRC to expand its capacity by around 40-60%.

Key Points: 
  • This 'hospital at home' will allow the SUHRC to expand its capacity by around 40-60%.
  • The 'hospital at home' system, delivered by Atos and built by Huma, is based on Huma's award-winning1 remote patient monitoring system that has already been used across England and Germany.
  • Clinicians can manage multiple patients, and with the available inputs can conduct consultations and care for their patients remotely.
  • "This symbiotic industry-academia partnership will help us deploy technology to provide healthcare services to patients in and around Pune.

Atos and Huma support Symbiosis Hospital in Pune to expand care capacity by up to 60% with new remote patient app

Retrieved on: 
Wednesday, December 1, 2021
Patient, Euronext Paris, National Digital Preservation Program, SIU, CEO, Heart rate, Technology, Biomarker, Outline of health sciences, Health care, Hospital, Population, Awareness, Partnership, Societas Europaea, ESG, Group, Heart of England NHS Foundation Trust, Education, Faculty, Solution, SE, Founder, COVID-19, Society, CAC, Research, National Digital Health Mission, CAC Next 20, Telehealth, Digital technology, Symbiosis International University, Smartphone, Digital, Knowledge, RADIUS, Disease, McMaster Faculty of Health Sciences, National, Pharmaceutical industry

This 'hospital at home' will allow the SUHRC to expand its capacity by around 40-60%.

Key Points: 
  • This 'hospital at home' will allow the SUHRC to expand its capacity by around 40-60%.
  • The 'hospital at home' system, delivered by Atos and built by Huma, is based on Huma's award-winning1 remote patient monitoring system that has already been used across England and Germany.
  • Clinicians can manage multiple patients, and with the available inputs can conduct consultations and care for their patients remotely.
  • "This symbiotic industry-academia partnership will help us deploy technology to provide healthcare services to patients in and around Pune.

Eiger BioPharmaceuticals to Host and Webcast Virtual Key Opinion Leader Event on Hepatitis Delta Virus Monday, November 15

Retrieved on: 
Tuesday, November 2, 2021
KOL, Cirrhosis, MD, Research, AASLD, Diagnosis, University, Ben-Gurion University of the Negev, Disease, Association, Institute of Liver and Biliary Sciences, Lonafarnib, Global health, PALO, AM, Outline of health sciences, III, Faculty, Patient, American Association for the Study of Liver Diseases, Liver cancer, Hepatitis B virus, HBsAg, Center, McMaster Faculty of Health Sciences, Liver disease, Non-alcoholic fatty liver disease, International, Company, Transplant, Viral hepatitis, Investor relations, Eiger, Fondazione Child, American Association, Therapy, Liver failure, HDV, Coinfection, Doctor of Philosophy, University of Milan, HBV, Department, Pharmaceutical industry, Medicine, Fine chemical, Vaccine

PALO ALTO, Calif., Nov. 2, 2021 /PRNewswire/ --Eiger BioPharmaceuticals, Inc.(Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announcedthat it will host a virtual Key Opinion Leader (KOL) event focused on Hepatitis Delta Virus (HDV) infection.

Key Points: 
  • PALO ALTO, Calif., Nov. 2, 2021 /PRNewswire/ --Eiger BioPharmaceuticals, Inc.(Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announcedthat it will host a virtual Key Opinion Leader (KOL) event focused on Hepatitis Delta Virus (HDV) infection.
  • The event is scheduled to take place on Monday, November 15, 2021 from9:00-10:30 AM ETand will be simultaneously webcast.
  • The live and replayed webcast of the event will be available through the Investor Relations "Events & Presentations" section of the company's website at www.eigerbio.com .
  • His most recent project involves treatment of hepatitis Delta patients with Lonafarnib and Peginterferon Lambda.

Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program (CORAL) Against SARS-CoV-2 Variants of Concern

Retrieved on: 
Tuesday, August 17, 2021
Vaccine, Epidemic, National Institute of Allergy and Infectious Diseases, University, NIAID, COVID, Program, SAGE, Faculty, Severe acute respiratory syndrome coronavirus 2, U.S. Securities and Exchange Commission, Infection, Immune system, GLOBE, CEPI, Gilead Sciences, Antigen, COVAX, La Jolla Institute for Immunology, CORAL, University of the Witwatersrand, Outline of health sciences, Cell, HIV, National, Bill & Melinda Gates Foundation, Immunodeficiency, Epitope, Coalition, Clinical trial, RNA transfection, Immunology, SAM, McMaster Faculty of Health Sciences, Volunteering, Coalition for Epidemic Preparedness Innovations, Patient, Solution, CEO, Bill, NIH, Neoplasm, SLATE, COVID-19, National Institute, Convalescence, Security (finance), Pharmaceutical industry

With this unique antigenic breadth, our CORAL vaccine may offer protection against emerging spike variants of SARS-CoV-2 that appear challenging for first generation vaccines, said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone.

Key Points: 
  • With this unique antigenic breadth, our CORAL vaccine may offer protection against emerging spike variants of SARS-CoV-2 that appear challenging for first generation vaccines, said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone.
  • Under the terms of the agreement, CEPI will fund a multi-arm Phase 1 study evaluating the CORAL programs SAM vaccine in nave, convalescent, and HIV+ patients.
  • Gritstones CORAL program is a second-generation SARS-CoV-2 vaccine platform delivering spike and additional SARS-CoV-2 T cell epitopes, offering the potential for deep, broad, and durable protection against SARS-CoV-2 variants.
  • Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences.

CATALYST Presents Foundation announces collaboration with Queen's University's Faculty of Health Sciences to host first in-person CATALYST Summit in Kingston, Ontario

Retrieved on: 
Monday, August 16, 2021
Linda, COVID-19, Osler Library of the History of Medicine, Queen, Fungus, Therapy, Psychedelic drug, History of medicine, Movement, Science, AB, University, Faculty, School, Department, Partnership, Research, Doctor of Philosophy, Conference, Outline of health sciences, University of Saskatchewan, Executive, MPH, Policy, Sale, Queen's University, Canada Research Chair, McMaster Faculty of Health Sciences, Professor, Queen's Faculty of Health Sciences, University School, Safety, Den, New York University Grossman School of Medicine, Education, Medical school, Salon (website), Industry, Summit, Nightclub, Pharmaceutical industry

CATALYST Summit 2022 event founder, David Harder, saw the potential to work with the Faculty of Health Sciences at Queen's University when the opportunity presented itself in the spring.

Key Points: 
  • CATALYST Summit 2022 event founder, David Harder, saw the potential to work with the Faculty of Health Sciences at Queen's University when the opportunity presented itself in the spring.
  • "It fits with our initiative to present CATALYST as Canada's premiere, 'must attend' medical, research, and business psychedelics conference."
  • Stay tuned for more details on this new and exciting component to CATALYST Summit 2022.
  • Rakesh Jain, MD, MPH, Clinical Professor, Department of Psychiatry, Texas Tech Health Sciences Centre, School of Medicine, Midland, Texas.

VAC announces creation of second Centre of Excellence

Retrieved on: 
Monday, July 29, 2019
Pain, Perception, McMaster University, Nociception, Pain management, Acute pain, McMaster Faculty of Health Sciences, Chronic pain, Chronic condition

The Centre of Excellence will focus on the creation and distribution of knowledge and research on chronic pain, one of the most prevalent health concerns among the Canadian Veteran population.

Key Points: 
  • The Centre of Excellence will focus on the creation and distribution of knowledge and research on chronic pain, one of the most prevalent health concerns among the Canadian Veteran population.
  • McMaster University is well-positioned to host the Centre of Excellence on Chronic Pain, as it currently houses both the Michael G. DeGroote National Pain Centre and Michael G. DeGroote Institute for Pain Research and Care (IPRC).
  • "The research conducted by the new Centre of Excellence on Chronic Pain will allow the delivery of the best chronic pain treatments and supports for Canada's Veterans.
  • McMaster will be a fantastic home for the Centre of Excellence for Chronic Pain."